Evaluation and Management of Hypoactive Sexual Desire Disorder [PDF]
Sexual Medicine, 2018 Introduction: Hypoactive sexual desire disorder (HSDD) often has a negative impact on the health and quality of life of women; however, many women do not mention—let alone discuss—this issue with their physicians.
Anita H. Clayton, MD +2 more
doaj +5 more sources
Hypoactive sexual desire disorder caused by antiepileptic drugs
Journal of Human Reproductive Sciences, 2015 Female sexual dysfunction is common but poorly understood sexual problem in women. Sexual dysfunction in female is multi-factorial in origin and also observed with intake of drug acting on central nervous system.
M Singh +3 more
doaj +4 more sources
Systematic Review of l-Arginine for the Treatment of Hypoactive Sexual Desire Disorder and Related Conditions in Women [PDF]
Pharmacy, 2021 This systematic review evaluates the efficacy and safety of l-arginine alone or in combination for the treatment of women with hypoactive sexual desire disorder (HSDD) or related conditions, such as female sexual interest/arousal disorder and female ...
Nicole E. Cieri-Hutcherson +6 more
doaj +2 more sources
Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder [PDF]
Sexual Medicine, 2022 : Introduction: Flibanserin treatment increases sexual desire and satisfying sexual events while decreasing distress in certain women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD).
James A. Simon, MD +6 more
doaj +2 more sources
Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin [PDF]
Sexual Medicine, 2022 : Background: The efficacy of flibanserin in treating hypoactive sexual desire disorder (HSDD) is based upon statistically significant improvements in sexual desire, satisfying sexual events, and distress.
James A. Simon, MD +3 more
doaj +2 more sources
Characteristics of Chinese women in need of enhanced sexual health attention and at risk of hypoactive sexual desire disorder [PDF]
BMC Women's Health, 2023 Background The target population for women’s sexual health services in China was unclear. To identify high-risk individuals with psychological barriers to sexual health-seeking behaviors and those at high risk of hypoactive sexual desire disorder (HSDD),
Lan Luo, Jingjing Huang, Huafang Li
doaj +2 more sources
Socio-demographic determinants of low sexual desire and hypoactive sexual desire disorder: a population-based study in Iran [PDF]
BMC Women's Health, 2020 Background Various socio-demographic factors have been introduced as the determinants of Low Sexual Desire (LSD), but whether these variables can also contribute to the Hypoactive Sexual Desire Disorder (HSDD), remains uncertain. In this study, we sought
Zeinab Hamzehgardeshi +5 more
doaj +2 more sources
Prevalence of Hypoactive Sexual Desire Disorder Among Sexually Active Postmenopausal Women With Metabolic Syndrome at a Public Hospital Clinic in Brazil: A Cross-sectional Study [PDF]
Sexual Medicine, 2020 Aims: To evaluate the prevalence of hypoactive sexual desire disorder (HSDD) among postmenopausal women diagnosed with metabolic syndrome (MS) and to compare it to that of a control group without MS.
Gustavo Maximiliano Dutra da Silva, MD, PhD +4 more
doaj +2 more sources
Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder [PDF]
The Journal of Clinical Investigation, 2022 BACKGROUND Hypoactive sexual desire disorder (HSDD) is characterized by a persistent deficiency of sexual fantasies and desire for sexual activity, causing marked distress and interpersonal difficulty.
Layla Thurston +16 more
doaj +2 more sources
Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder [PDF]
Journal of Patient-Reported Outcomes, 2020 Background The Elements of Desire Questionnaire (EDQ) is a patient-reported outcome (PRO) measure developed to evaluate sexual desire and was included in two identically designed phase 3 clinical trials (RECONNECT) as an exploratory endpoint. The EDQ was
Dennis A. Revicki +8 more
doaj +2 more sources